
PEPTEXA LABORATORIES

OVER 10 YEARS
working with research peptides

EVERY BATCH INDEPENDENTLY TESTED IN EUROPE

TIRZEPATIDE

Tirzepatide; a dual GIP / GLP-1 receptor agonist



GIP + GLP-1 receptors → **Appetite / glucose signals** → **Weight / metabolic endpoints**

Simplified research schematic - not a clinical outcome image.

RESEARCH FOCUS

- **Body-weight reduction**
- **Waist-circumference reduction**
- **Glucose-regulation research**

WHAT IT IS

Tirzepatide is a peptide designed to activate both GIP and GLP-1 receptors. These receptors participate in the body’s response to food and the regulation of blood glucose.

HOW IT WORKS / HOW IT IS STUDIED

Its dual receptor activity affects glucose-dependent insulin secretion and appetite-related processes. Clinical research measures how these effects translate into weight and metabolic changes.

RESEARCH CONTEXT

Randomised human trials have evaluated weight-related outcomes in defined populations. Published findings concern the trial formulations and cannot verify the performance of every catalogue presentation.

SELECTED SCIENTIFIC REFERENCES

PubMed 40353578 - view study

Research summaries describe the cited materials and study settings, not guaranteed product outcomes.

CONTACT PEPTEXA FOR MORE INFORMATION

WhatsApp +34 634 321 402 | Product details and batch reports

Company history and testing statements supplied by Peptexa. | Research information | 21 November 2026